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Abstract
There is a critical need for new influenza vaccines able to protect against constantly emerging divergent virus strains. This
will be sustained by the induction of vigorous cellular responses and humoral immunity capable of acting at the portal of
entry of this pathogen. In this study we evaluate the protective efficacy of intranasal vaccination with recombinant influenza
nucleoprotein (rNP) co-administrated with bis-(39,59)-cyclic dimeric adenosine monophosphate (c-di-AMP) as adjuvant.
Immunization of BALB/c mice with two doses of the formulation stimulates high titers of NP-specific IgG in serum and
secretory IgA at mucosal sites. This formulation also promotes a strong Th1 response characterized by high secretion of INF-
c and IL-2. The immune response elicited promotes efficient protection against virus challenge. These results suggest that c-
di-AMP is a potent mucosal adjuvant which may significantly contribute towards the development of innovative mucosal
vaccines against influenza.
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Introduction
Seasonal vaccination against influenza is the best available
measure to reduce the high impact of this pathogen on public
health worldwide. However, the immunity conferred by current
vaccines is sub-optimal. For example: i) the degree of coverage is
low and variable and seasonal vaccine only protects against viruses
which share a high degree of homology with the original vaccine
strain [1,2] ii) most vaccines are administered parentally, leading
to unsatisfactory mucosal responses [3,4], and iii) the elicitation of
cell mediate immunity is very poor or absent [5,6].
The efficacy of current vaccines is mainly based on the
induction of neutralizing antibodies that target the surface viral
protein hemagglutinin (HA). This protein is subjected to a high
degree of antigenic variation and new divergent strains continu-
ously arise in nature, which are not recognized by antibodies
induced by the vaccine. As a consequence, the vaccine seed stocks
need to be updated every year [7]. To overcome this limitation,
efforts were invested in the development of a vaccine that can
protect against the multiple antigenic variants, a concept that is
known as ‘‘universal vaccine’’ [8]. This concept is based on the use
of conserved antigens, such as the amino terminus of the M2
protein (M2e or M2 ectodomain) [9], the conserved stalk domain
of the HA [10], the M1 protein and the nucleoprotein (NP)
[11,12].
The strategy based on the use of M1 or NP as antigens is based
on the elicitation of strong cell-mediated immunity rather than the
induction of neutralizing antibodies. Such approach has been
termed as "T-cell vaccine" [13,14]. In this regard, it has been
recognized for over 30 years that adoptive transfer of lymphocytes
from influenza infected mice to naı¨ve animal confer protection to
recipients against different viral strains, the so-called heterotypic
immunity [15,16]. It was also demonstrated that the NP represents
a major recognition target [17–19]. Although there are several
other viral proteins bearing T-cell epitopes able to induce this type
of immunity, NP stands as one of the most conserved and effective
target antigen [20,21]. Numerous studies showed that immuniza-
tion with recombinant NP can confer protection against experi-
mental infection with divergent viruses. In some cases protection
was principally mediated by CD4+ and by CD8+ T cells [22–28].
Unexpectedly, recent studies have shown that non-neutralizing
anti-NP antibodies elicited in vaccinated animals can also confer
protection against influenza infection [29–32].
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Up to now, the most effective strategy to obtain protection in
vaccinated animals using conserved antigens has been the
generation of recombinant viral vectors (e.g. adenoviruses or
poxviruses) expressing M1 and NP proteins [11,12,33]. The
vaccinia virus based approach has been successfully tested in
human trials [12,13]. However, the use of live vectors (e.g.
adenoviral vectors) for mass vaccination campaigns is associated
with potential safety issues [34].
Furthermore, another limitation of most current available
vaccines is that they are administered by the intramuscular route,
thereby not leading to the stimulation of mucosal immune
responses. There is only one intranasal influenza vaccine in the
market which is based on a live attenuated virus (FluMist,
MedImmune, USA). However, mucosal vaccination could estab-
lish a first line of defense at the mucosal tissues, the portal of entry,
for this important pathogen [35,36]. Thus, important features of a
new generation influenza vaccine would be their capacity to
induce strong humoral and cellular immune responses even at
mucosal territories [35–37]. The combination of a conserved
influenza antigen with an efficient mucosal adjuvant could be a
good approach to achieve this goal [35,36,38–40].
We observed in previous studies that the bis-(39,59)-cyclic
dimeric adenosine monophosphate (c-di-AMP) combined with
model antigens, such as OVA or b-Gal, acts as a potent mucosal
adjuvant stimulating both humoral and cellular responses [41].
Here, in the present work we demonstrated that intranasal
administration of a rNP influenza vaccine with c-di-AMP, results
in the stimulation of both humoral and cellular specific immune
responses at both systemic and mucosal levels, which confer
efficient protection against influenza viral challenge.
Material and Methods
Immunization schedule and vaccines
Groups of female BALB/c (H-2d) mice (n = 5) of 6 to 8 weeks of
age purchased from Harlan Winckelmann GmbH (Borchen,
Germany) were immunized on days 0 and 21 by intranasal route.
The recombinant influenza nucleoprotein (rNP), derived from the
influenza strain A/PR/8/34 (H1N1), was synthesized and purified
as previously described [42]. The synthesis and purification of the
mucosal adjuvant c-di-AMP was described in Ebensen et al [41].
For vaccine preparation, lyophilized c-di-AMP was freshly
dissolved in distilled water. Mice received 10 mg/dose of rNP
alone or co-administered with 10 mg/dose of c-di-AMP as
adjuvant. A negative control group received phosphate buffered
saline (PBS). The solutions were prepared in PBS 30 min before
administration (final volume of 20 ml; 10 ml per nostril). To
facilitate animal manipulations mice were shortly anesthetized
with Isofluorane (Abbott Animal Health), according to the
manufacturer’s instructions. Animals were breed at the animal
facility of the Helmholtz Centre for Infection Research under
specific pathogen free conditions with food and water ad libitum.
All animal experiments in this study have been performed in
agreement with the local government of Lower Saxony (Ger-
many), under the animal permission code No. 33.11.42502-04-
017/08.
Sample collection
Blood samples were collected on days 0, 21 and 42 via retro-
bulbar bleeding. The samples were incubated for 60 min at 37uC
and for 30 min at 4uC, then centrifuged to remove red blood cells
(5 min at 8,0006g) and sera were stored at 220uC until
processing. Then, mice were sacrificed and broncho-alveolar
(BAL) and nasal lavages (NL) were obtained by flushing the local
tissues with ice-cold PBS supplemented with 5% FCS (Greiner
Bio-One, USA) and 40 mM phenyl-methane-sulfonyl-fluoride
(PMSF). Lavages were centrifuged (5 min at 8.000 g) to remove
debris and stored at 220uC until processing for the detection of
immunoglobulin A (IgA). Cells from spleen were collected and
monitored for the presence of antigen-specific T and B lympho-
cytes. Subsequently spleen was taken aseptically and disaggregated
in complete RPMI (RPMI 1640 supplemented with 10% fetal calf
serum, 100 U/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml
gentamycin; Gibco, USA). For the depletion of the erythrocytes
the pellet was re-suspended in ACK lysis buffer. After washing, cell
suspensions were cultured in complete RPMI and used for the
determination of cellular immune responses. Cellular responses
were analyzed using pools of spleen cells, whereas antibodies were
examined by investigating individual animals.
Elispot assays
To determine gamma interferon (IFN-c), interleukin-2 (IL-2),
interleukin-4 (IL-4) and interleukin-17 (IL-17) secreting cells,
murine IFN-c, IL-2, IL-4 and IL-17, enzyme-linked immunospot
(ELISPOT) kits (BD Pharmingen, USA) were performed, accord-
ing to the manufacturer’s instructions. Cells (16106 or 56105
cells/well) were incubated for 24 h (IFN-c) or 48 h (IL-2, IL-17
and IL-4) at 37uC with 5% CO2, in the absence or presence of
2 mg/ml of rNP, or an immune-dominant MHC class I restricted
peptide (NP 147–155) or a mix of MHC class II restricted peptides
(NP 182-205, NP 55-77 and NP 206-229), which were synthesized
at the HZI. After 24 or 48 h, cells were removed and the plates
were processed according to the manufacturer’s instructions.
Colored spots were counted with an ELISPOT reader (CTL S5
Micro Analyzer) and analyzed using ImmunoSpot image analyzer
software v3.2 (CTL Europe GmbH, Germany).
Determination of NP-specific IgG in serum
The NP-specific antibodies were determined by enzyme-linked
immunosorbent assay (ELISA) using microtiter plates coated with
100 ml/well of rNP (2 mg/ml in carbonate buffer; pH 8.2). After
overnight incubation at 4uC, plates were blocked with 3% BSA in
PBS for 1 h at 37uC. Serial two-fold dilutions of sera in 1% BSA–
PBS were added (100 ml/well), and plates were incubated for 2 h
at 37uC. After six washes with 3% BSA–PBS–0.05% Tween 20,
secondary antibodies were added: biotinylated chain-specific goat
anti-mouse IgG (Sigma, USA) or, to determine IgG subclasses,
biotinylated rat anti-mouse IgG1, IgG2a and IgG3 (BD Pharmin-
gen, USA). Plates were further incubated for 2 h at 37uC. After six
washes, 100 ml/well of peroxidase conjugated streptavidin (BD
Pharmingen, USA) was added to each well, and plates were
incubated at room temperature for 1 h. After another six washes,
reactions were developed using ABTS [2,2-azinobis(3-ethyl-
benzthiazoline-6-sulfonic acid)] in 0.1 M citrate-phosphate buffer
(pH 4.35) containing 0.01% H2O2. End-point ELISA titers were
expressed as the reciprocal of the highest sample dilution that
yielded an OD $2 times above the mean value of the blank.
Determination of NP-specific IgA in mucosal lavages
The amount of antigen-specific IgA presents in the NL and BAL
were determined by ELISA, as previously described by Ebensen et
al. [41]. Briefly, 96 well microtitre plates were coated with 100 ml
per well of rNP in a concentration of 2 mg/ml, diluted in
carbonate buffer and incubated for 2 h. After blocking with 3%
BSA/PBS for 1 h at 37uC, the plates were washed and further
incubated with 2-fold serial diluted lavages samples for 1 h at
37uC. After 6 washes, biotinylated alpha-chain specific goat anti-
mouse IgA (Southern Biotech, USA) was added and plates were
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further incubated for 1 h at 37uC. After 66 washes, the
peroxidase-conjugated streptavidine (BD Pharmingen, USA) was
added and the plates were incubated at RT for 1 h. The plates
were washed and reactions were developed using ABTS in 0.1 M
citrate–phosphate buffer (pH 4.35) containing 0.01% H2O2. To
compensate variations in the efficiency of recovery of secretory
antibodies among animals, the results were normalized and
expressed as endpoint titers of antigen-specific IgA per mg of total
IgA present in the sample. In brief, plates coated with 2 mg/ml of
goat anti-mouse IgA (Sigma) as capture antibody were incubated
with serial twofold dilutions of either lavage samples or, for the
standard curve, purified mouse IgA (Dianova, Hamburg, Ger-
many) for 1 h. After serial washes with PBS plus 0.1% Tween 20,
plates were incubated for 1 h with the secondary antibody,
biotinylated goat anti-mouse IgA (Southern Biotech, USA),
washed six times, and developed as described above.
Proliferation
Pooled spleen cells (56105 cells/well) of each vaccination group
were incubated in quadruplicates for 96 h in the presence of
different concentrations of, rNP (0.1, 1 and 2 mg/ml), a peptide
encompassing a MHC class I-restricted epitope (NP 147-155) or a
pool of peptides spanning different MHC class II-restricted
epitopes (NP 182-205, NP 55-77 and NP 206-229) (0.2, 2 and
4 mg/ml). Eighteen hours before harvesting, 1 mCi of [3H]
thymidine (Amersham International, Freiburg, Germany) was
added to each well. Then, cells were harvested on paper filters
(Filtermat A; Wallac, Freiburg, Germany) using a cell harvester
(Inotech, Wohlen, Switzerland) and the incorporation of [3H]
thymidine into the DNA of proliferating cells was determined
using a scintillation counter (Wallac 1450, Micro-Trilux). The
results are presented as stimulation index (SI). For the calculation
of the SI the counts per minute (cpm) of antigen-stimulated
samples (0.2, 2 and 4 mg/ml) were divided by cpm of unstimulated
samples (0 mg/ml).
Challenge
Groups (n = 6) of female BALB/c (H-2d) were immunized on
day 0 and 21 with rNP (10 mg/dose) alone or co-administered with
c-di-AMP (10 mg/dose) by intranasal route, whereas control
animals received PBS. All groups were challenged on day 60 with
a sub-lethal dose of the influenza strain A/Puerto Rico/8/34
(H1N1) (50 FFU/0.5 LD50). To this end, mice were anesthetized
by intraperitoneal injection with Ketamine/xylazine combination
with a dose adjusted to the individual body weight (200 ml/20 g).
The virus was administered in a total volume of 20 ml, 10 ml per
nostril. Following infection, mice were monitored daily for
morbidity during two weeks.
Statistical analysis
Statistical analysis was performed with GraphPad Prism (version
5.01), software. The data was presented as mean 6SEM.
Difference between groups were analyzed by Student’s t-test and
one way ANOVA. Differences were considered significant at p,
0.05.
Results
The immunization with rNP co-administered with c-di-
AMP elicits strong antigen-specific humoral immune
responses at systemic and mucosal levels
Current influenza vaccines should be endowed with the capacity
to induce an efficient humoral response, ideally, both at systemic
and mucosal levels. We evaluated the capacity of rNP adjuvanted
with c-di-AMP to induce humoral and cellular immune responses
when given by intranasal route. NP was chosen as antigen due to
the fact that this protein is one of the most promising candidates
for the development of an influenza vaccine with broader cross-
protective activity. In addition, rNP could be produced in E. coli at
high yields and comparatively low costs [42]. To this end, groups
of BALB/c mice were immunized by intranasal route with two
doses of 10 mg of rNP alone, or co-administered with 10 mg of c-di-
AMP, at an interval of three weeks. Immunized mice were bled six
weeks after the second immunization and NP-specific total IgG
and IgG subclass titers (e.g. IgG1, IgG2a and IgG3) were
determined in serum by ELISA (Fig. 1). Sera of mice immunized
with rNP co-administered with c-di-AMP showed high titers with
an 239-fold increase of antigen-specific IgG, when compared with
those from animals receiving rNP alone. The analysis of the IgG
subclass titers showed that significantly enhanced NP specific
IgG2a, IgG1, and IgG3 titers, with a preferential induction of the
IgG2a subclass (IgG2a/IgG1 ratio 2.2) indicating a Th1 bias
immune response. To evaluate the immune responses induced by
the vaccine formulation at mucosal level, titers of NP-specific IgA
in NL and BAL were determined by ELISA (Fig. 2). Similarly to
what happened with the systemic response, strong responses were
obtained by inclusion of c-di-AMP in the formulation. This is
really important considering the fact that the primary replication
site of influenza virus is the lung.
Intranasal administration of rNP co-administered with
c-di-AMP induces strong cellular immune responses
It has been previously reported that c-di-AMP is also capable of
inducing a strong cellular response to co-administered antigens
[41]. Thus, we evaluated if the novel NP vaccine formulation was
also able to promote antigen-specific cellular responses. To this
end, animals were sacrificed three weeks after the second
immunization and the capacity of splenocytes to produce IL-2,
INF-c, IL-17 and IL-4 after re-stimulation with rNP or peptides
corresponding to NP epitopes recognized in the context of MHC
class I or class II molecules was determined by ELISPOT. In mice
immunized with rNP co-administered with c-di-AMP strong
cellular responses characterized by enhanced secretion of INF-c,
IL-2 and IL-17, whereas only a weak production of IL-4 was
observed (Fig. 3), thereby suggesting the stimulation of a dominant
Th1/Th17 response [41]. The analysis of T cell responses after re-
stimulation with MHC class II or class I restricted peptides
indicated that responses were mainly driven by CD4+ T cells.
In addition, proliferative responses of splenocytes obtained from
immunized mice after in vitro re-stimulation with rNP or peptides
were evaluated (Fig. 4). Strong responses were observed in animals
vaccinated with rNP co-administered with c-di-AMP. Moreover,
strong proliferation was observed after stimulation with MHC
class II peptides, thereby confirming that the cellular response is
mainly driven by CD4+ T cells. In contrast, no or only weak
stimulation was observed when spleen cells from mice vaccinated
with rNP alone or PBS after were analyzed. This is in line with the
ELISPOT results which also showed no or only weak stimulation
when stimulated with a MHC class I specific peptide (data not
shown).
Mice vaccinated with rNP co-administered with c-di-AMP
are protected against challenge with the H1N1 influenza
virus
Mice vaccinated with rNP alone or co-administered with c-di-
AMP were challenged at day 60 post priming with the influenza
Intranasal Delivery of Influenza rNP Adjuvanted with c-di-AMP
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strain A/PR/8/34 (H1N1) and their body weight was recorded
daily for at least two weeks as indicator for the ongoing infection
disease (Fig. 5). From day 2 after challenge onwards, control mice
and animals vaccinated with rNP alone started to develop signs of
disease, such as loss of body weight, ruffled fur and lethargy. At
days 8-9 post challenge, all mice of the control and rNP-alone
groups showed signs of illness (e.g. ruffled fur and/or lethargy),
indicated by a loss of 10 to 13% of their original body weight. In
contrast, mice immunized with rNP co-administered with c-di-
AMP showed no weight loss or side effects after challenge. Taken
together, these results confirm that the immune responses induced
by intranasal vaccination with rNP co-administered with c-di-
AMP confer protection against influenza virus infection.
Discussion
Current influenza vaccines have certain shortcomings, including
their reduced capacity to induce cellular and mucosal immunity.
Provision of such attributes would markedly improve the
performance of existing vaccines. Therefore, different approaches
have been explored to overcome these problems, such as the use of
alternative routes of immunization. In this regard, mucosal
administration represents an attractive approach to promote
immune responses at the pathogen portal entry. However, purified
antigens are per se poor immunogenic when administered by
different mucosal routes (e.g. oral). This can be overcome by co-
administration with appropriate mucosal adjuvants.
Previous studies from our group suggested that the cyclic di-
nucleotides are potent mucosal adjuvants, which are also able to
promote efficient and humoral and cellular immune responses
when co-administered with the hemagglutinin of the influenza
virus, including stimulation of multi-functional T cells [41,43–48].
Thus, in the current study we assess the effectiveness of c-di-AMP
adjuvant co-administered with a rNP-based subunit influenza
vaccine. We demonstrated that intranasal administration of rNP/
c-di-AMP vaccine results in enhanced humoral and cellular
immune responses at both systemic and mucosal levels, which
confer effective protection against influenza infection.
Increased serum levels of NP antigen-specific antibodies, were
observed in mice vaccinated with rNP/c-di-AMP vaccine (Fig. 1).
Although specific IgG-NP antibodies have no neutralizing activity,
their importance should not be neglected. Several studies
suggested that they could contribute significantly to protection
against influenza infection by different antiviral mechanisms.
These studies have shown that NP-containing immune-complexes
released from infected cells could bind to Fc receptors on dendritic
cells, thereby enhancing antigen presentation and subsequent viral
clearance of infected cells by CD8+ T cells [49,50]. Furthermore,
it was demonstrated that vaccination strategies to boost existing
anti-NP Abs levels, can contribute to long term hetero-subtype
immunity [50]. Based on these attributes it was suggested that the
capacity to stimulate anti-NP IgG may be a critical feature of a
universal influenza vaccine [49].
Another prominent feature of the rNP/c-d-AMP vaccine was
the induction of a vigorous NP specific IgA response in NL and
Figure 1. Evaluation of NP specific IgG and IgG subclasses in serum. Anti-NP IgG titers were determined by ELISA on day 60. BALB/c mice
(n = 5) were vaccinated with two doses of rNP (10 mg/dose) alone or co-administered with c-di-AMP (10 mg/dose) by intranasal route, whereas control
animals received PBS, at an interval of 3 weeks. (A) Anti-NP IgG titer. (B) Anti-NP IgG subclass titers. The results are expressed as mean end point titers.
The S.E.M. is indicated by vertical lines. Differences were statistically significant at p,0.01 (**) or p,0.05 (*) with respect to values obtained in mice
receiving the antigen alone.
doi:10.1371/journal.pone.0104824.g001
Figure 2. Evaluation of NP specific IgA in mucosal lavages. NP-
specific IgA titers measured by ELISA in nasal (NL) and BAL lavages of
BALB/c mice immunized with two doses of rNP (10 mg/dose) alone or
co-administered with c-di-AMP (10 mg/dose) by intranasal route at an
interval of 3 weeks. Control animals received PBS. Results are expressed
as NP specific IgA titer. The S.E.M. is indicated by vertical lines.
Differences were statistically significant at p,0.001 (***) and p,0.01
(**), compared with the titers in mice immunized with rNP alone.
doi:10.1371/journal.pone.0104824.g002
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BAL secretions. This is particularly important since the influenza
virus is a respiratory pathogen, colonizing trachea, bronchi and
pulmonary alveoli as sites of viral replication. It is tempting to
speculate that this IgA might also contribute to cross-protection by
a process known as intracellular neutralization. Intracellular
neutralization of viruses is a process whereby IgA antibodies
may neutralize viral replication by binding to newly synthesized
viral proteins after being internalized in infected cells. It has been
demonstrated that IgA can be internalized within epithelial cells
by the polymeric immunoglobulin receptor (pIgR), and inside the
cell it can be able to bind to newly synthesized viral proteins,
preventing viral assembly and neutralizing viral infection. It was
shown that this mechanism works with various viruses (e.g.
influenza, sendai, measles, HIV, etc.) and it may be mediated by
Figure 3. Analysis NP-specific cellular responses induced by vaccination. Splenocytes from immunized groups of mice were incubated for
24 or 48 h in the presence of rNP or peptides encompassing MHC class I and class II restricted epitopes of NP. The number of IFN-c (A), IL-2 (B), IL-4 (C)
and IL-17 (D) producing cells was then determined by ELISPOT. Results are expressed as number of spots of cells producing cytokines per 106 spleen
cells after subtraction of background values of unstimulated cells. The differences are statistically significant p,0.001 (***) compared to the results of
cells obtained from mice vaccinated with rNP alone.
doi:10.1371/journal.pone.0104824.g003
Figure 4. Analysis of proliferative responses in vaccinated mice. Splenocytes from immunized groups of mice were re-stimulated for 96 h
with different concentrations of rNP (A) or a pool of peptides encompassing a MHC class II restricted epitopes of NP. Cellular proliferation was
measured by incorporation of [3H] thymidine into the DNA. The results are represented as stimulation index (SI).
doi:10.1371/journal.pone.0104824.g004
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antibodies recognizing the envelope proteins as well as the internal
proteins of the virus as is the case of influenza NP [51–56].
Another appealing attribute of the rNP/c-di-AMP vaccine is its
extraordinary ability to induce a strong cellular response. Cytokine
profiles of splenocytes from immunized mice showed a strong
secretion of IL-2 and INF-c compared to the values from mice
receiving rNP alone (Fig. 3), thereby suggesting a Th1 dominating
immune response.
In addition we showed, that splenocytes restimulated with NP
are able to secrete remarkable IL-17 levels, which is consistent
with previously reported results on the use of c-di-AMP as mucosal
adjuvant [41]. The true role of IL-17 in influenza infection is still a
matter of debate, with evidence supporting its contribution to both
pathogenic or protective processes [57–61]. It has been indicated
that IL-17 may have a beneficial role at the level of bronchial
mucosa against respiratory pathogens through the induction of
polymeric Ig receptor expression in the airway epithelium and by
enhancing the secretory IgA levels [62]. It was also demonstrated
that in IL-10-deficient mice there is an increased expression of
several Th17 cytokines in the lungs and this correlates with a
dramatically higher survival compared with wild-type mice when
challenged with lethal doses of virus [58]. There is some evidence
suggesting that the use of Th17 inducing adjuvants may result in
increased morbidity and exacerbated lung injury upon subsequent
influenza infection [63]. In our study no signs of exacerbate
morbidity was observed in mice vaccinated with rNP/c-di-AMP
post challenge. We showed that a balanced Th1/Th17 profile is
important to influenza protection. Nevertheless, a better under-
standing of the role played by different subsets of IL-17 producing
cells during influenza infection, as well as on the viral clearance or
immune pathological mechanisms to which these cells contribute
will be helpful to understand true impact of IL-17 regulation or
dysregulation during infection and vaccination.
In addition, our results showed that the rNP/c-di-AMP vaccine
induces potent CD4 response after stimulation with MHC class II
NP restricted peptides. Recent reports have suggested the
importance of memory CD4+ T cells in influenza infection, as a
result of their synergistic helper functions with B or T cells, as well
as their contribution to the elimination of escape viral mutants in
absence of B cells or CD8+ T cells [31,64,65]. Thus, the
development of vaccines able to trigger strong CD4+ responses
could be central for the induction of memory responses capable of
combating divergent influenza viruses through multiple pathways.
In this context, there is experimental evidence on NP-based
vaccines which promote CD4+ T cell responses contributing
towards protective immunity [22,66]. This phenomenon is not
restricted only to influenza, since numerous infectious models have
demonstrated the importance of CD4+ T cells in cellular mediated
protection [67,68].
Taken together, the quality of the immune response stimulated
by intranasal administration with rNP/c-di-AMP vaccine was
clearly demonstrated by the protection conferred by this formu-
lation against a challenge with the influenza virus. This study
clearly demonstrated that c-di-AMP is a promising mucosal
adjuvant, which should be exploited to develop innovative
vaccines against seasonal and pandemic influenza.
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